- About us
- Clinical trials
- News & Publications
October 9, 2019
Source: Oncoimmunology. 2019 Oct 9;9(1):1671763. doi: 10.1080/2162402X.2019.1671763. eCollection 2020.
Authors: J. Fucikova, J.P. Kline, L. Galluzzi, R. Spisek.
Calreticulin (CALR) exposed on the surface of cancer cells succumbing to therapy delivers robust phagocytic signals that support the activation of adaptive anticancer immune responses. Recent data from our group demonstrate that spontaneous CARL exposure on leukemic blasts also supports innate anticancer immunity by natural killer (NK) cells via an indirect mechanism relying on myeloid CD11c+CD14+ cells.